Gossamer Bio Inc

Gossamer Bio Inc is an international clinical-stage biopharmaceutical company engaged in the discovery, acquisition, development, and commercialisation of therapeutics in the areas of immunology, inflammation, fibrosis, and oncology, with a focus on novel and differentiated therapies to address unmet needs among specific patient populations. Operating worldwide, the firm was established in 2015 and has its headquarters in San Diego, California, with a European office in Dublin, Ireland. The firm has a number of products in the pipeline, mainly aimed at treating patients with pulmonary arterial hypertension, ulcerative colitis, primary SCS lymphoma, and multiple sclerosis. The firm aims to be an industry leader in each of the major therapeutic areas it focuses on, supported by its team of industry veterans, clinicians, scientists, and thought leaders in biotechnology, along with partnerships with leading academic centres around the world. The firm was founded by the former Receptos executive leadership team, including Faheem Hasnain and Sheila Gujrathi, M.D., after Receptos was acquired by Celgene in 2014. Gossamer Bio went public in 2016, just 13 months after its launch. The firm is listed on the NASDAQ, where it trades under the ticker GOSS. Get news and updates on price changes by adding GOSS stock to your eToro watchlist.